NASDAQ
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a free cash flow growth of -26.70% as of Friday, May 29, 2026. This represents a 225.86% decrease compared to its 12-month average of -8.19%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.